A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension

Trial Profile

A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs MK 5478 (Primary) ; Candesartan cilexetil
  • Indications Hypertension
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 12 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top